- Home
- RAND vs SCYX Comparison
RAND vs SCYX Comparison
Compare RAND & SCYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RAND
- SCYX
- Stock Information
- Founded
- RAND 1969
- SCYX 1999
- Country
- RAND United States
- SCYX United States
- Employees
- RAND N/A
- SCYX N/A
- Industry
- RAND Finance: Consumer Services
- SCYX Biotechnology: Pharmaceutical Preparations
- Sector
- RAND Finance
- SCYX Health Care
- Exchange
- RAND Nasdaq
- SCYX Nasdaq
- Market Cap
- RAND 47.5M
- SCYX 50.3M
- IPO Year
- RAND N/A
- SCYX 2014
- Fundamental
- Price
- RAND $16.40
- SCYX $1.20
- Analyst Decision
- RAND
- SCYX Buy
- Analyst Count
- RAND 0
- SCYX 1
- Target Price
- RAND N/A
- SCYX N/A
- AVG Volume (30 Days)
- RAND 2.2K
- SCYX 165.3K
- Earning Date
- RAND 11-06-2024
- SCYX 11-06-2024
- Dividend Yield
- RAND 7.07%
- SCYX N/A
- EPS Growth
- RAND 123.39
- SCYX N/A
- EPS
- RAND 4.98
- SCYX N/A
- Revenue
- RAND $8,351,941.00
- SCYX $8,566,000.00
- Revenue This Year
- RAND N/A
- SCYX N/A
- Revenue Next Year
- RAND N/A
- SCYX $145.59
- P/E Ratio
- RAND $3.30
- SCYX N/A
- Revenue Growth
- RAND 16.96
- SCYX N/A
- 52 Week Low
- RAND $12.50
- SCYX $1.15
- 52 Week High
- RAND $19.60
- SCYX $3.07
- Technical
- Relative Strength Index (RSI)
- RAND 50.67
- SCYX 28.95
- Support Level
- RAND $16.05
- SCYX $1.25
- Resistance Level
- RAND $16.46
- SCYX $1.37
- Average True Range (ATR)
- RAND 0.11
- SCYX 0.06
- MACD
- RAND 0.04
- SCYX -0.01
- Stochastic Oscillator
- RAND 75.47
- SCYX 9.26
About RAND Rand Capital Corporation
Rand Capital Corp is a closed-end, diversified management company. The firm's investment objectives is to maximize the total return to the shareholders with current income combined with capital appreciation. Some of its portfolios include lumious, and GiveGab among others.
About SCYX SCYNEXIS Inc.
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against a broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.